[go: up one dir, main page]

DK3274340T3 - Hæmmere af hepatitis c-viruspolymerase - Google Patents

Hæmmere af hepatitis c-viruspolymerase Download PDF

Info

Publication number
DK3274340T3
DK3274340T3 DK16717211.3T DK16717211T DK3274340T3 DK 3274340 T3 DK3274340 T3 DK 3274340T3 DK 16717211 T DK16717211 T DK 16717211T DK 3274340 T3 DK3274340 T3 DK 3274340T3
Authority
DK
Denmark
Prior art keywords
hepatitis
inhibitors
virus polymerase
polymerase
virus
Prior art date
Application number
DK16717211.3T
Other languages
English (en)
Inventor
Irina C Jacobson
Michael D Feese
Sam S Lee
Original Assignee
Cocrystal Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cocrystal Pharma Inc filed Critical Cocrystal Pharma Inc
Application granted granted Critical
Publication of DK3274340T3 publication Critical patent/DK3274340T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Furan Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
DK16717211.3T 2015-03-23 2016-03-23 Hæmmere af hepatitis c-viruspolymerase DK3274340T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562136857P 2015-03-23 2015-03-23
PCT/US2016/023664 WO2016154241A1 (en) 2015-03-23 2016-03-23 Inhibitors of hepatitis c virus polymerase

Publications (1)

Publication Number Publication Date
DK3274340T3 true DK3274340T3 (da) 2019-10-07

Family

ID=55759915

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16717211.3T DK3274340T3 (da) 2015-03-23 2016-03-23 Hæmmere af hepatitis c-viruspolymerase

Country Status (18)

Country Link
US (2) US10464914B2 (da)
EP (1) EP3274340B1 (da)
JP (1) JP6741747B2 (da)
KR (1) KR20170137113A (da)
CN (1) CN107567442B (da)
AU (1) AU2016235246B2 (da)
CA (1) CA2979555C (da)
DK (1) DK3274340T3 (da)
EA (1) EA033622B1 (da)
ES (1) ES2748974T3 (da)
IL (1) IL254243B (da)
MX (1) MX379015B (da)
NZ (1) NZ735093A (da)
PH (1) PH12017501687A1 (da)
PL (1) PL3274340T3 (da)
SG (1) SG11201707527YA (da)
TW (1) TWI731854B (da)
WO (1) WO2016154241A1 (da)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI731854B (zh) * 2015-03-23 2021-07-01 美商共結晶製藥公司 C型肝炎病毒聚合酶之抑制劑
US11752166B2 (en) * 2018-05-09 2023-09-12 Cocrystal Pharma, Inc. Combination therapy for treatment of HCV
CN112745216A (zh) * 2019-10-30 2021-05-04 常州锐博生物科技有限公司 一种4-溴甲基苯甲酸甲酯及其衍生物的制备方法
US12274700B1 (en) 2020-10-30 2025-04-15 Accencio LLC Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors
CN114181187A (zh) * 2021-11-24 2022-03-15 上海应用技术大学 一种4-甲磺酰胺基丁酰胺化合物的制备方法
CN116283512B (zh) * 2023-02-24 2025-04-25 博诺康源(北京)药业科技有限公司 一种合成维兰特罗及其盐的方法
WO2025111414A1 (en) * 2023-11-21 2025-05-30 Katholieke Universiteit Leuven Trpm3-modulating benzofuran derivatives
CN119350612B (zh) * 2024-12-24 2025-10-24 浙江爱索拓标记医药科技有限公司 一种放射性同位素碳-14标记聚乙二醇单甲醚的合成方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ305166A (en) 1995-03-20 1998-12-23 Lilly Co Eli 5-substituted-3-(1,2,3,6-tetrahydropyridin-4-yl)- and 3-(piperidin-4-yl)-1h-indoles; preparation and medicaments
US6350458B1 (en) 1998-02-10 2002-02-26 Generex Pharmaceuticals Incorporated Mixed micellar drug deliver system and method of preparation
PL395097A1 (pl) 2001-06-11 2011-10-10 Vertex Pharmaceuticals (Canada) Incorporated Sposób wytwarzania związku o wzorze A stanowiącego pochodną tiofenu
EP1395571A1 (en) 2001-06-11 2004-03-10 Shire Biochem Inc. Compounds and methods for the treatment or prevention of flavivirus infections
DE60221627D1 (de) 2001-12-21 2007-09-20 Virochem Pharma Inc Thiazolderivate und ihre Verwendung zur Behandlung oder Vorbeugung von Infektionen durch Flaviviren
WO2004041201A2 (en) * 2002-11-01 2004-05-21 Viropharma Incorporated Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis c viral infections and associated diseases
WO2004052879A1 (en) 2002-12-10 2004-06-24 Virochem Pharma Inc. Thiophenederivatives for the treatment of flavivirus infections
EP1569929B9 (en) 2002-12-10 2011-09-14 Virochem Pharma Inc. Compounds and methods for the treatment or prevention of flavivirus infections
ES2345438T3 (es) 2002-12-10 2010-09-23 Virochem Pharma Inc. Compuestos y metodos para el tratamiento o prevencion de infecciones por flavivirus.
MXPA06013338A (es) 2004-05-20 2007-02-22 Sugen Inc Tiofen-heteroaril-aminas.
DE102004061746A1 (de) 2004-12-22 2006-07-06 Bayer Healthcare Ag Alkinyl-substituierte Thiophene
EP2546246A3 (en) 2005-05-13 2013-04-24 Virochem Pharma Inc. Compounds and methods for the treatment or prevention of flavivirus infections
EP1971599A1 (en) 2005-12-22 2008-09-24 SmithKline Beecham Corporation Antiviral 2-carboxy-thiophene compounds
WO2008017688A1 (en) 2006-08-11 2008-02-14 Smithkline Beecham Corporation 2-carboxy thiophene derivatives as anti-viral agents
TW200815384A (en) 2006-08-25 2008-04-01 Viropharma Inc Combination therapy method for treating hepatitis C virus infection and pharmaceutical compositions for use therein
WO2008043791A2 (en) 2006-10-13 2008-04-17 Smithkline Beecham Corporation Thiophene derivatives for treating hepatitis c
EA201101492A1 (ru) 2006-11-15 2012-09-28 Вирокем Фарма Инк. Аналоги тиофена для лечения или предупреждения флавивирусных инфекций
ATE524465T1 (de) 2006-11-17 2011-09-15 Glaxosmithkline Llc 2-carboxy-thiophen-derivate als viruzide
GB0707092D0 (en) 2007-04-12 2007-05-23 Smithkline Beecham Corp Compounds
GB0712393D0 (en) 2007-06-26 2007-08-01 Smithkline Beecham Corp Compounds
GB0718435D0 (en) * 2007-09-21 2007-10-31 Northern Health And Social Car Wpund care formulation
CA2714254A1 (en) 2008-02-14 2009-08-20 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
WO2009137500A1 (en) * 2008-05-05 2009-11-12 Wyeth 6-substituted benzofuran compounds to treat infection with hepatitis c virus
AR080433A1 (es) * 2010-03-02 2012-04-11 Merck Sharp & Dohme Derivados de benzofurancarboxamidas utiles para tratar o prevenir infecciones por vhc y composiciones farmaceuticas que los contienen.
WO2011106929A1 (en) 2010-03-02 2011-09-09 Merck Sharp & Dohme Corp. Inhibitors of hepatitis c virus ns5b polymerase
AR082453A1 (es) * 2010-04-21 2012-12-12 Novartis Ag Compuestos de furopiridina, composiciones farmaceuticas que los contienen y usos de los mismos
AU2011329485A1 (en) * 2010-11-18 2013-04-18 Glaxo Group Limited Compounds
TW201307334A (zh) 2010-12-17 2013-02-16 Cocrystal Discovery Inc C型肝炎病毒聚合酶抑制劑
WO2014055142A1 (en) 2012-06-20 2014-04-10 Cocrystal Discovery, Inc. Inhibitors of hepatitis c virus polymerase
TWI731854B (zh) * 2015-03-23 2021-07-01 美商共結晶製藥公司 C型肝炎病毒聚合酶之抑制劑

Also Published As

Publication number Publication date
AU2016235246A1 (en) 2017-09-21
IL254243B (en) 2020-10-29
JP6741747B2 (ja) 2020-08-19
US10464914B2 (en) 2019-11-05
CN107567442B (zh) 2021-05-25
HK1249514A1 (en) 2018-11-02
US10947210B2 (en) 2021-03-16
US20180050998A1 (en) 2018-02-22
HK1243703A1 (zh) 2018-07-20
PL3274340T3 (pl) 2020-01-31
MX379015B (es) 2025-03-10
PH12017501687A1 (en) 2018-03-19
EP3274340A1 (en) 2018-01-31
CA2979555C (en) 2023-12-19
BR112017020168A2 (pt) 2018-06-05
TWI731854B (zh) 2021-07-01
EA033622B1 (ru) 2019-11-11
WO2016154241A1 (en) 2016-09-29
AU2016235246B2 (en) 2020-12-10
TW201643147A (zh) 2016-12-16
KR20170137113A (ko) 2017-12-12
CN107567442A (zh) 2018-01-09
ES2748974T3 (es) 2020-03-18
IL254243A0 (en) 2017-10-31
JP2018512453A (ja) 2018-05-17
EP3274340B1 (en) 2019-07-17
NZ735093A (en) 2022-09-30
US20200255393A1 (en) 2020-08-13
MX2017012238A (es) 2018-02-15
CA2979555A1 (en) 2016-09-29
EA201792094A1 (ru) 2018-03-30
SG11201707527YA (en) 2017-10-30

Similar Documents

Publication Publication Date Title
DK3512850T3 (da) Inhibitorer af menin-mll-interaktionen
IL259077A (en) Vaccines against hepatitis b virus
DK3377059T3 (da) Hæmmere af cxcr2
DK3468966T3 (da) Inhibitorer af menin-mll-interaktionen
DK3371171T3 (da) Inhibitorer af RET
DK3102576T3 (da) Dihydropyrrolopyridininhibitorer af ror-gamma
DK3366295T3 (da) Fremgangsmåder til behandling af filoviridae virusinfektioner
DK3805376T3 (da) Modificeret virus
DK3137169T3 (da) Hæmmere af lysin-specifik demethylase-1
DK3684377T3 (da) Fremgangsmåder til behandling af hepatitis-b-infektion
DK3164380T3 (da) Hæmmere af lysinspecifik demethylase-1
DK3325662T3 (da) Epigenetisk inaktivering af nmt2
DK3201361T3 (da) Fremgangsmåder til kvantificering af cellefrit DNA
DK3274340T3 (da) Hæmmere af hepatitis c-viruspolymerase
DK3180331T3 (da) Polymorfer af selinexor
DK3254092T3 (da) Bestemmelse af en vægs termiske modstand
DK3329007T3 (da) Ortogonal afblokering af nukleotider
DK3512857T3 (da) Spiro-bicykliske inhibitorer af menin-mll-interaktion
DK3371165T3 (da) Btk-inhibitor til anvendelse til behandling af kræft
DK3436074T3 (da) Thiazolidforbindelser til behandling af virale infektioner
DK3137078T3 (da) Behandling af hepatitis delta-virusinfektion
DK3307267T3 (da) Behandling af multipel sklerose
DK3204352T3 (da) Hæmmere af lysin-gingipain
DK3370723T3 (da) Behandling af hepatitis delta-virusinfektion
DK3380982T3 (da) Håndtering af genom forespørgsel